Sign In
Buy WGS
$53.02
-0.110 (-0.207%)
At Close: Jun 03, 2026
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx announced it will unveil research findings during four key sessions at the 2025 National Society of Genetic Counselors (NSGC) Annual Meeting.
Y Intercept Hong Kong Ltd Takes $589,000 Position in GeneDx Holdings Corp. $WGS
04:13am, Thursday, 06'th Nov 2025
Y Intercept Hong Kong Ltd bought a new stake in GeneDx Holdings Corp. (NASDAQ: WGS) in the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC).
GeneDx Holdings Corp. (WGS) Q3 2025 Earnings Call Transcript
03:41pm, Tuesday, 28'th Oct 2025
GeneDx Holdings Corp. (NASDAQ:WGS ) Q3 2025 Earnings Call October 28, 2025 8:30 AM EDT Company Participants Sabrina Dunbar Katherine Stueland - President, CEO & Director Kevin Feeley - Chief Financial
GeneDx Holdings Corp. (WGS) Q3 Earnings and Revenues Surpass Estimates
08:46am, Tuesday, 28'th Oct 2025
GeneDx Holdings Corp. (WGS) came out with quarterly earnings of $0.49 per share, beating the Zacks Consensus Estimate of $0.28 per share. This compares to earnings of $0.04 per share a year ago.
GeneDx Reports Third Quarter 2025 Financial Results and Business Highlights
06:30am, Tuesday, 28'th Oct 2025
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx Holdings Corp. (Nasdaq: WGS) today reported its financial results for the third quarter of 2025.
GeneDx: A Moment Of Reckoning As Market Awaits Q3 Testing Growth
08:00am, Monday, 27'th Oct 2025
GeneDx Holdings Corp. is poised for strong Q3 results, driven by expanding exome and genome testing in pediatric and neonatal settings. Key metrics for WGS include test volume growth and reimbursement
GeneDx Holdings Corp. (NASDAQ: WGS) Investor Reminder: Schubert Jonckheer Investigating Possible False Claims
08:00am, Monday, 27'th Oct 2025
SAN FRANCISCO , Oct. 27, 2025 /PRNewswire/ -- Schubert Jonckheer & Kolbe LLP reminds GeneDx Holdings Corp. (NASDAQ: WGS) investors that the firm is investigating potential legal claims relating to w
VIRGINIA RETIREMENT SYSTEMS ET Al Takes Position in GeneDx Holdings Corp. $WGS
04:38am, Sunday, 26'th Oct 2025
VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new stake in shares of GeneDx Holdings Corp. (NASDAQ: WGS) in the second quarter, according to its most recent filing with the SEC. The firm purchased 5,4
GeneDx Holdings Corp. (NASDAQ:WGS) Given Consensus Rating of “Moderate Buy” by Brokerages
01:37am, Sunday, 26'th Oct 2025
Shares of GeneDx Holdings Corp. (NASDAQ: WGS - Get Free Report) have been assigned an average rating of "Moderate Buy" from the twelve brokerages that are currently covering the firm, Marketbeat Ratin
Halper Sadeh LLC Encourages GeneDx Holdings Corp. Shareholders to Contact the Firm to Discuss Their Rights
09:40am, Friday, 24'th Oct 2025
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of GeneDx Holdings Corp. (NASDAQ: WGS) breached their fiduciary duties
GeneDx Showcases Leadership in Genomic Newborn Screening at ICoNS 2025
08:00am, Wednesday, 22'nd Oct 2025
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx Showcases Leadership in gNBS at ICoNS 2025 with data from more than 22,000 newborns.
GeneDx Granted FDA Breakthrough Device Designation for its ExomeDx™ and GenomeDx™ Testing
08:00am, Monday, 20'th Oct 2025
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx announces that the FDA has granted Breakthrough Device Designation for its whole genome and exome tests.
GeneDX CEO Katherine Stueland on how the company is using AI to save lives
03:30pm, Wednesday, 15'th Oct 2025
GeneDX CEO Katherine Stueland discusses how the company is using AI to help deliver "life-changing information." Want to hear the full interview?
GeneDX CEO Katherine Stueland on conquering imposter syndrome
01:30pm, Wednesday, 15'th Oct 2025
GeneDX CEO Katherine Stueland shares her advice for conquering imposter syndrome with CNBC's Julia Boorstin: "Step into the deep end." Want to hear the full interview?
GeneDX CEO Katherine Stueland on if the cuts at NIH impact the company
11:45am, Wednesday, 15'th Oct 2025
GeneDX CEO Katherine Stueland talks about the impact of federal funding cuts to research programs. Want to hear the full interview?
